Simon Jones
Director of Finance/CFO at Karus Therapeutics Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Simon Kerry | M | - |
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | 18 years |
| Jonathan Mussellwhite | M | 57 |
OMERS Private Equity Europe Ltd.
| 10 years |
| Michael Bloch Hansen | M | - |
OMERS Private Equity Europe Ltd.
| 15 years |
| Stephanie Brady | F | - |
OMERS Private Equity Europe Ltd.
| 6 years |
| Marie Le Moel | F | - |
OMERS Private Equity Europe Ltd.
| 5 years |
| Matt James Baird | M | 51 |
OMERS Private Equity Europe Ltd.
| - |
| Emilio Tercero-Mora Rodriguez | M | - |
OMERS Private Equity Europe Ltd.
| 6 years |
| Bart de Jong | M | - |
OMERS Private Equity Europe Ltd.
| 5 years |
| Sam Williams | M | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | - |
| Tim Edwards | M | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | 6 years |
| Kate Bingham | F | 58 |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | - |
| Madeleine Cavadias | F | - |
OMERS Private Equity Europe Ltd.
| 8 years |
| Elisabeth A. Bone | M | - |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | 11 years |
| James Frankish | M | 42 |
OMERS Private Equity Europe Ltd.
| 7 years |
| Laura Marie Coquis Power | F | - |
OMERS Private Equity Europe Ltd.
| 15 years |
| Liam Ratcliffe | M | 60 |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | - |
| Martin Edwards | M | 68 |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | - |
| Michael Paul Graham | M | 58 |
OMERS Private Equity Europe Ltd.
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Redman | M | - |
OMERS Private Equity Europe Ltd.
| 11 years |
| Charles Miller-Jones | M | 42 |
OMERS Private Equity Europe Ltd.
| 4 years |
| Kenton Bradbury | M | 53 |
OMERS Private Equity Europe Ltd.
| 6 years |
| Scott Hauser | M | - |
OMERS Private Equity Europe Ltd.
| 2 years |
| Bryony Marshall | F | - |
OMERS Private Equity Europe Ltd.
| - |
| Matthieu Sagnier | M | - |
OMERS Private Equity Europe Ltd.
| - |
| James Sexton | M | - |
OMERS Private Equity Europe Ltd.
| 2 years |
| Ioana Chivu | M | - |
OMERS Private Equity Europe Ltd.
| - |
| Daniel Teutsch | M | - |
OMERS Private Equity Europe Ltd.
| 3 years |
| Alejandro Lopez Delgado | M | - |
OMERS Private Equity Europe Ltd.
| 8 years |
| Maxime Menu | M | - |
OMERS Private Equity Europe Ltd.
| 3 years |
| Isabelle Pagnotta | F | - |
OMERS Private Equity Europe Ltd.
| 9 years |
| Lavanya Bhamidipati | F | - |
OMERS Private Equity Europe Ltd.
| - |
| Gareth Fitzgerald | M | - |
OMERS Private Equity Europe Ltd.
| 2 years |
| Victoire Piens | F | - |
OMERS Private Equity Europe Ltd.
| - |
| Simren Priestley | F | - |
OMERS Private Equity Europe Ltd.
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 34 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Simon Jones
- Personal Network
